SCHEMBL30347771

SCHEMBL30347771

CN1CCN(c2cc(Nc3ncc4c(-c5cc6cnccc6s5)c[nH]c4n3)ccn2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLK2 P49760 1/20 0.62
▸ CLK3 P49761 1/20 0.62
▸ DYRK1A Q13627 1/20 0.62
▸ CDK2 P24941 5/20 0.42
▸ FLT3 P36888 2/20 0.42
▸ CDK1 P06493 1/20 0.42
▸ CCNB1 P14635 1/20 0.42
▸ CCNE1 P24864 1/20 0.42
▸ CDK7 P50613 1/20 0.42
▸ CCNH P51946 1/20 0.42
▸ MNAT1 P51948 1/20 0.42
▸ DYRK1B Q9Y463 3/20 0.41
▸ IGF1R P08069 2/20 0.41
▸ MTOR P42345 1/20 0.38
▸ SMG1 Q96Q15 1/20 0.38
▸ WEE1 P30291 1/20 0.37
▸ PIM1 P11309 1/20 0.37
▸ PIM3 Q86V86 1/20 0.37
▸ PIM2 Q9P1W9 1/20 0.37
▸ AURKA O14965 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25157096 1.00 CLK2 (0.62) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL25157128 0.90 CLK2 (0.49) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL30348555 0.90 CLK2 (0.49) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL30348604 0.87 CDK2 (0.56) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL25218717 0.87 CDK2 (0.56) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL25157832 0.83 DYRK1A (0.43) CLK2CLK3DYRK1ACDK2DYRK1B
SCHEMBL30346882 0.83 DYRK1A (0.43) CLK2CLK3DYRK1ACDK2DYRK1B
SCHEMBL25562899 0.83 DYRK1A (0.76) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL25198845 0.82 DYRK1A (0.39) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL30406338 0.82 DYRK1A (0.39) CLK2CLK3DYRK1ACDK2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 — — US claimed
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 CLK2 466/4885CLK3 1147/4885DYRK1A 1/4885
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 CLK2 466/4885CLK3 1147/4885DYRK1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback